Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan.
PLoS One. 2013 Apr 22;8(4):e61666. doi: 10.1371/journal.pone.0061666. Print 2013.
Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among cirrhotic patients at different clinical stages, and to identify the associated risk factors. The medical records of 713 patients with acute variceal bleeding who had received endoscopic procedures from were reviewed. Three hundred and eleven patients were entered for age-matched adjustment after strict exclusion criteria. After the adjustment, a total of 102 patients were enrolled and sorted into 2 groups according to the severity of cirrhosis: group A (Child's A patients, n = 51) and group B (Child's B and C patients, n = 51). The outcomes were prevention of infection, time of rebleeding, and death. Our subgroup analysis results failed to show a significant difference in infection prevention between patients who received prophylactic cefazolin and those who received ceftriaxone among Child's A patients (93.1% vs. 90.9%, p = 0.641); however, a trend of significance in favor of ceftriaxone prophylaxis (77.8% vs. 87.5%, p = 0.072) was seen among Child's B and C patients. More rebleeding cases were observed in patients who received cefazolin than in those who received ceftriaxone among Child's B and C patients (66.7% vs. 25.0%, p = 0.011) but not in Child's A patients (32% vs. 40.9%, p = 0.376). The risk factors associated with rebleeding were history of bleeding and use of prophylactic cefazolin among Child's B and C patients. In conclusion, this study suggests that prophylactic intravenous cefazolin may not be inferior to ceftriaxone in preventing infections and reducing rebleeding among Child's A cirrhotic patients after endoscopic interventions for acute variceal bleeding. Prophylactic intravenous ceftriaxone yields better outcome among Child's B and C patients.
环丙沙星、诺氟沙星和头孢曲松等抗生素预防性治疗已被推荐用于有胃肠道出血的肝硬化患者,但关于头孢唑啉的静脉应用知之甚少。本研究旨在比较头孢唑啉和头孢曲松作为预防性抗生素在不同临床分期的肝硬化患者中的疗效,并确定相关的危险因素。对接受内镜治疗的 713 例急性静脉曲张出血患者的病历进行了回顾性研究。严格排除标准后,有 311 例患者进入年龄匹配调整。调整后,共纳入 102 例患者,并根据肝硬化严重程度分为 2 组:A 组(Child A 患者,n = 51)和 B 组(Child B 和 C 患者,n = 51)。结果为预防感染、再出血时间和死亡。我们的亚组分析结果显示,头孢唑啉组和头孢曲松组预防感染在 Child A 患者中无显著差异(93.1% vs. 90.9%,p = 0.641);然而,头孢曲松组有预防感染的趋势(77.8% vs. 87.5%,p = 0.072)在 Child B 和 C 患者中更为明显。Child B 和 C 患者中,头孢唑啉组再出血例数多于头孢曲松组(66.7% vs. 25.0%,p = 0.011),而 Child A 患者中两组无差异(32% vs. 40.9%,p = 0.376)。Child B 和 C 患者再出血的相关危险因素是出血史和预防性使用头孢唑啉。总之,本研究表明,对于内镜治疗急性静脉曲张出血后的 Child A 肝硬化患者,预防性静脉使用头孢唑啉在预防感染和减少再出血方面可能并不逊于头孢曲松。头孢曲松在 Child B 和 C 患者中效果更好。